OBJECTIVES: To determine adenosine deaminase (ADA) activity as a possible diagnostic marker in HIV and HIV-HBV co-infected patients. DESIGN AND METHODS: Blood samples were collected from 72 healthy, 33 HIV positive and 30 HIV-HBV co-infected subjects. Blood CD4+ cell count was recorded and serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total ADA, and ADA1 and ADA2 isoenzyme activities were determined. RESULTS: Serum ALT, AST, total ADA and ADA2 isoenzyme activities were significantly higher in HIV positive and HIV-HBV co-infected groups compare to the control (p<0.05), whereas serum ALP showed no differences between groups. CD4+ cell counts markedly decreased in all patients and showed a significant inverse correlation with ADA activities (R(2)=0.589, p<0.001). CONCLUSIONS: Serum ADA was significantly increased in HIV and HIV-HBV co-infections. Therefore, because of its low cost and simplicity to perform, ADA activity might be considered as a useful diagnostic tool among the other markers in these diseases.
OBJECTIVES: To determine adenosine deaminase (ADA) activity as a possible diagnostic marker in HIV and HIV-HBV co-infectedpatients. DESIGN AND METHODS: Blood samples were collected from 72 healthy, 33 HIV positive and 30 HIV-HBV co-infected subjects. Blood CD4+ cell count was recorded and serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total ADA, and ADA1 and ADA2 isoenzyme activities were determined. RESULTS: Serum ALT, AST, total ADA and ADA2 isoenzyme activities were significantly higher in HIV positive and HIV-HBV co-infected groups compare to the control (p<0.05), whereas serum ALP showed no differences between groups. CD4+ cell counts markedly decreased in all patients and showed a significant inverse correlation with ADA activities (R(2)=0.589, p<0.001). CONCLUSIONS: Serum ADA was significantly increased in HIV and HIV-HBV co-infections. Therefore, because of its low cost and simplicity to perform, ADA activity might be considered as a useful diagnostic tool among the other markers in these diseases.
Authors: Ana María Gutiérrez; Ernesto De La Cruz-Sánchez; Ana Montes; Juan Sotillo; Cándido Gutiérrez-Panizo; Pablo Fuentes; Pedro Luis Tornel; Juan Cabezas-Herrera Journal: PLoS One Date: 2017-06-08 Impact factor: 3.240
Authors: Rekha Dhanwani; Mariko Takahashi; Ian T Mathews; Camille Lenzi; Artem Romanov; Jeramie D Watrous; Bartijn Pieters; Catherine C Hedrick; Chris A Benedict; Joel Linden; Roland Nilsson; Mohit Jain; Sonia Sharma Journal: Sci Adv Date: 2020-07-22 Impact factor: 14.136